دورية أكاديمية
أعرض في EDS

Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer.

التفاصيل البيبلوغرافية
العنوان: Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer.
المؤلفون: Chauhan G; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, NB-40, 9500 Euclid Avenue, Cleveland, OH 44195, USA., Heemers HV; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, NB-40, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
المصدر: Cancers [Cancers (Basel)] 2021 Aug 05; Vol. 13 (16). Date of Electronic Publication: 2021 Aug 05.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Inhibiting the activity of the ligand-activated transcription factor androgen receptor (AR) is the default first-line treatment for metastatic prostate cancer (CaP). Androgen deprivation therapy (ADT) induces remissions, however, their duration varies widely among patients. The reason for this heterogeneity is not known. A better understanding of its molecular basis may improve treatment plans and patient survival. AR's transcriptional activity is regulated in a context-dependent manner and relies on an interplay between its associated transcriptional regulators, DNA recognition motifs, and ligands. Alterations in one or more of these factors induce shifts in the AR cistrome and transcriptional output. Significant variability in AR activity is seen in both castration-sensitive (CS) and castration-resistant CaP (CRPC). Several AR transcriptional regulators undergo somatic alterations that impact their function in clinical CaPs. Some alterations occur in a significant fraction of cases, resulting in CaP subtypes, while others affect only a few percent of CaPs. Evidence is emerging that these alterations may impact the response to CaP treatments such as ADT, radiation therapy, and chemotherapy. Here, we review the contribution of recurring somatic alterations on AR cistrome and transcriptional output and the efficacy of CaP treatments and explore strategies to use these insights to improve treatment plans and outcomes for CaP patients.
References: Cancer Cell. 2016 Jun 13;29(6):846-858. (PMID: 27238081)
Cell. 2015 May 21;161(5):1215-1228. (PMID: 26000489)
Nat Rev Urol. 2018 May;15(5):271-286. (PMID: 29460922)
Sci Transl Med. 2012 Mar 28;4(127):127rv3. (PMID: 22461644)
Trends Endocrinol Metab. 2010 May;21(5):315-24. (PMID: 20138542)
Hum Mutat. 2016 Jan;37(1):52-64. (PMID: 26411452)
J Urol. 1989 May;141(5):1139-42. (PMID: 2651713)
Cancer Res. 2006 Mar 1;66(5):2815-25. (PMID: 16510604)
J Clin Oncol. 2011 Jun 20;29(18):2565-73. (PMID: 21606417)
Endocr Relat Cancer. 2004 Jun;11(2):281-93. (PMID: 15163303)
Trends Biochem Sci. 2015 Jan;40(1):16-24. (PMID: 25435400)
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6997-7002. (PMID: 23559371)
J Clin Oncol. 2019 Apr 10;37(11):923-931. (PMID: 30811282)
J Urol. 1986 Nov;136(5):1038-40. (PMID: 3095566)
Nat Med. 2016 Apr;22(4):369-78. (PMID: 26928463)
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3100-5. (PMID: 16492776)
Lancet Oncol. 2016 Nov;17(11):1612-1620. (PMID: 27743920)
J Clin Oncol. 2018 Apr 10;36(11):1080-1087. (PMID: 29384722)
Clin Cancer Res. 2018 Aug 15;24(16):3908-3916. (PMID: 29760221)
Mol Cancer Res. 2019 Aug;17(8):1699-1709. (PMID: 31068457)
Oncotarget. 2012 Feb;3(2):183-94. (PMID: 22383394)
Mol Cell Endocrinol. 2014 Aug 5;393(1-2):75-82. (PMID: 24911885)
Adv Exp Med Biol. 2008;617:87-95. (PMID: 18497033)
Asian J Urol. 2020 Jul;7(3):219-232. (PMID: 32742924)
J Clin Invest. 2014 Nov;124(11):5013-26. (PMID: 25295534)
Cancer Cell. 2010 Jul 13;18(1):11-22. (PMID: 20579941)
Endocr Rev. 2007 Dec;28(7):778-808. (PMID: 17940184)
Cancer Res. 2007 Apr 1;67(7):3422-30. (PMID: 17409453)
J Cell Sci. 2008 Apr 1;121(Pt 7):957-68. (PMID: 18319300)
Cancer Discov. 2018 Apr;8(4):444-457. (PMID: 29367197)
Front Oncol. 2018 Sep 24;8:397. (PMID: 30319966)
BMJ Open. 2019 Mar 8;9(3):e025161. (PMID: 30852544)
Science. 2009 Apr 17;324(5925):407-10. (PMID: 19372434)
Urology. 2020 Dec 26;:. (PMID: 33373705)
Database (Oxford). 2016 Feb 13;2016:. (PMID: 26876983)
BJU Int. 2021 Jun 25;:. (PMID: 34171173)
EMBO J. 2015 Feb 12;34(4):502-16. (PMID: 25535248)
Eur Urol. 2021 Mar 27;:. (PMID: 33785256)
Cancer Cell. 2017 Apr 10;31(4):532-548.e7. (PMID: 28344039)
Cancer Discov. 2012 Nov;2(11):995-1003. (PMID: 23093251)
Eur Urol Focus. 2019 Mar;5(2):111-113. (PMID: 30898552)
Urol Oncol. 2019 Apr;37(4):289.e1-289.e9. (PMID: 30679082)
Clin Cancer Res. 2019 Nov 15;25(22):6721-6730. (PMID: 31515456)
JCO Precis Oncol. 2018;2018:. (PMID: 30761387)
Eur Urol. 2015 Mar;67(3):470-9. (PMID: 25306226)
Int J Cancer. 2007 Feb 15;120(4):719-33. (PMID: 17163421)
Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4758-63. (PMID: 15037741)
Prostate. 2002 May 15;51(3):219-24. (PMID: 11967956)
Endocrinology. 2017 Jun 1;158(6):1533-1542. (PMID: 28368512)
EMBO J. 2011 May 20;30(13):2719-33. (PMID: 21602788)
Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):594-600. (PMID: 24515272)
EMBO J. 2011 Sep 13;30(19):3962-76. (PMID: 21915096)
Eur Urol. 2015 Jan;67(1):53-60. (PMID: 24882673)
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4904-9. (PMID: 11320241)
Mol Cell. 2020 Sep 3;79(5):812-823.e4. (PMID: 32668201)
Cancer Res. 2012 Dec 1;72(23):6142-52. (PMID: 22971343)
Cell Stem Cell. 2021 Jul 1;28(7):1262-1274.e5. (PMID: 33657416)
Mol Cancer Ther. 2015 Aug;14(8):1896-906. (PMID: 26026052)
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. (PMID: 31061129)
Mol Biosyst. 2012 Jan;8(1):82-90. (PMID: 21822504)
Clin Cancer Res. 2014 Jun 1;20(11):2846-50. (PMID: 24727321)
Nat Genet. 2015 Nov;47(11):1346-51. (PMID: 26457646)
Eur Urol Open Sci. 2020 Dec;22:34-44. (PMID: 33299986)
Prostate. 2009 Oct 1;69(14):1579-85. (PMID: 19575420)
Mol Cell. 2007 Aug 3;27(3):380-92. (PMID: 17679089)
Nat Commun. 2018 Jun 11;9(1):2256. (PMID: 29892050)
CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
J Natl Compr Canc Netw. 2021 Feb 02;19(2):134-143. (PMID: 33545689)
Endocr Relat Cancer. 2021 Jul 15;28(8):T67-T78. (PMID: 34111024)
Am J Clin Oncol. 2006 Feb;29(1):14-20. (PMID: 16462497)
Nat Med. 2015 Apr;21(4):344-52. (PMID: 25822367)
Eur Urol. 2018 May;73(5):715-723. (PMID: 29258679)
Endocr Relat Cancer. 2017 Aug;24(8):R275-R295. (PMID: 28566530)
Cancer Cell. 2011 May 17;19(5):575-86. (PMID: 21575859)
N Engl J Med. 2017 Jul 27;377(4):338-351. (PMID: 28578639)
J Clin Invest. 2021 May 17;131(10):. (PMID: 33998599)
Clin Cancer Res. 2013 Sep 15;19(18):5202-9. (PMID: 23918607)
Chem Res Toxicol. 2003 Oct;16(10):1338-58. (PMID: 14565775)
Cancer Discov. 2013 Nov;3(11):1245-53. (PMID: 24027196)
Cold Spring Harb Perspect Med. 2017 Sep 1;7(9):. (PMID: 28389515)
Urology. 2020 Nov;145:13-21. (PMID: 32866512)
J Clin Invest. 2021 May 17;131(10):. (PMID: 33998604)
Cancer Res. 2007 Jul 1;67(13):6083-91. (PMID: 17616663)
J Biol Chem. 2012 Feb 3;287(6):4000-13. (PMID: 22174411)
Nat Med. 2016 Mar;22(3):298-305. (PMID: 26855148)
Elife. 2017 Aug 18;6:. (PMID: 28826481)
Cancer Cell. 2011 Jun 14;19(6):792-804. (PMID: 21620777)
Cancer Cell. 2019 Dec 9;36(6):674-689.e6. (PMID: 31735626)
Eur Urol. 2017 Feb;71(2):183-192. (PMID: 27451135)
Clin Cancer Res. 2014 Dec 15;20(24):6269-76. (PMID: 25336698)
Nature. 2019 Jul;571(7765):408-412. (PMID: 31243370)
Clin Cancer Res. 2007 Apr 1;13(7):2030-7. (PMID: 17404083)
Eur Urol. 2015 May;67(5):825-36. (PMID: 25097095)
N Engl J Med. 2014 Sep 11;371(11):1028-38. (PMID: 25184630)
Nat Genet. 2018 May;50(5):645-651. (PMID: 29610475)
JAMA Oncol. 2017 Dec 1;3(12):1663-1672. (PMID: 28494073)
Nature. 2014 Jun 12;510(7504):278-82. (PMID: 24759320)
N Engl J Med. 2015 Aug 20;373(8):737-46. (PMID: 26244877)
Nat Commun. 2017 Feb 06;8:14388. (PMID: 28165461)
Cancer Cell. 2003 Sep;4(3):209-21. (PMID: 14522255)
Nat Rev Cancer. 2002 May;2(5):389-96. (PMID: 12044015)
Cancer Discov. 2013 Nov;3(11):1254-71. (PMID: 24027197)
Neoplasia. 2014 Jan;16(1):14-20. (PMID: 24563616)
Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944)
Lancet. 2016 Mar 19;387(10024):1163-77. (PMID: 26719232)
Cancer Discov. 2018 Mar;8(3):288-303. (PMID: 29301747)
Eur Urol. 2011 Nov;60(5):897-904. (PMID: 21802835)
J Urol. 2021 Jul;206(1):80-87. (PMID: 33683939)
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44. (PMID: 25024180)
Cancer Cell. 2010 May 18;17(5):443-54. (PMID: 20478527)
Oncogene. 2017 Mar 23;36(12):1655-1668. (PMID: 27669432)
J Mol Endocrinol. 2013 Nov 07;51(3):T1-T21. (PMID: 24103914)
Nucleic Acids Res. 2014 Jun;42(10):6256-69. (PMID: 24753418)
Oncotarget. 2017 Feb 7;8(6):10324-10347. (PMID: 28055971)
Nucleic Acids Res. 2020 May 21;48(9):4741-4755. (PMID: 32198885)
Cancer Cell. 2019 Apr 15;35(4):603-617.e8. (PMID: 30930119)
Ther Adv Urol. 2017 Nov 22;10(2):65-77. (PMID: 29434674)
Nat Commun. 2018 Nov 21;9(1):4900. (PMID: 30464211)
EMBO Rep. 2007 Sep;8(9):871-8. (PMID: 17721441)
Cancer Cell. 2013 Jan 14;23(1):35-47. (PMID: 23260764)
Clin Cancer Res. 2018 Nov 15;24(22):5585-5593. (PMID: 30068710)
Nat Commun. 2020 Apr 24;11(1):1987. (PMID: 32332823)
Nat Commun. 2020 Feb 11;11(1):832. (PMID: 32047165)
Endocr Relat Cancer. 2020 Mar;27(3):187-198. (PMID: 31951590)
معلومات مُعتمدة: R01 CA166440 United States CA NCI NIH HHS; R01 CA248048 United States CA NCI NIH HHS; CA166440, CA248048 United States CA NCI NIH HHS; Falk Catalyst Award Medical Research Trust
فهرسة مساهمة: Keywords: biomarker; castration; castration-resistant; castration-sensitive; disease stratification; genomics; hormonal therapy; personalized medicine; somatic alterations
تواريخ الأحداث: Date Created: 20210827 Latest Revision: 20211109
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8393938
DOI: 10.3390/cancers13163947
PMID: 34439101
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers13163947